Profile
Stewart M.
Kroll worked as a Director-Biostatistics at Coulter Pharmaceuticals, Inc. from 1997 to 2000.
He then worked as a Senior Director-Biostatistics at Corixa Corp.
from 2000 to 2005.
From 2005 to 2016, he served as the Chief Operating Officer at Threshold Pharmaceuticals, Inc. He was also the Senior Vice President at Biometrics, Inc. from 2017 to 2019.
In 2020, he became the Chief Development Officer at La Jolla Pharmaceutical Co. and held the position until 2022.
He also served as the Chief Development Officer at Odonate, Inc. from 2018 to 2021.
Kroll received his undergraduate and graduate degrees from the University of California, Berkeley.
Former positions of Stewart M. Kroll
| Companies | Position | End |
|---|---|---|
| LA JOLLA PHARMACEUTICAL COMPANY | Corporate Officer/Principal | 31/08/2022 |
| ODONATE, INC. | Corporate Officer/Principal | 30/09/2021 |
| Biometrics, Inc. | Corporate Officer/Principal | 31/12/2018 |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Chief Operating Officer | 29/09/2016 |
Corixa Corp.
 Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Corporate Officer/Principal | 31/12/2004 |
Training of Stewart M. Kroll
| University of California, Berkeley | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ODONATE, INC. | Health Technology |
| Private companies | 5 |
|---|---|
La Jolla Pharmaceutical Co.
 La Jolla Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. It engages in the discovery, development and commercialization of therapies intended to improve outcomes in patients suffering from life-threatening diseases. Its products portfolio include GIAPREZA and XERAVA. The company was founded in 1989 and is headquartered in San Diego, CA. | Health Technology |
Coulter Pharmaceuticals, Inc.
 Coulter Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Founded in 1995, Coulter Pharmaceutical is engaged in the development of novel drugs and therapies for the treatment of people with cancer and autoimmune diseases. Currently under development is a family of therapeutics based upon two drug discovery platforms: therapeutic antibodies and targeted oncologics. | Health Technology |
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Health Technology |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | Health Technology |
| Biometrics, Inc. | Technology Services |
- Stock Market
- Insiders
- Stewart M. Kroll
